Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

por Gopal, Srihari, Liu, Yanning, Alphs, Larry, Savitz, Adam, Nuamah, Isaac, Hough, David
Publicado 2013

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()

por Pandina, Gahan, Nuamah, Isaac, Petersen, Timothy, Singh, Jaskaran, Savitz, Adam, Hough, David
Publicado 2020

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, doub...

por Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Mathews, Maju, Soares, Bernardo
Publicado 2019

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

por Samtani, Mahesh N, Nuamah, Isaac, Gopal, Srihari, Remmerie, Bart, Kern Sliwa, Jennifer, Alphs, Larry
Publicado 2013

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophreni...

por Mathews, Maju, Nuamah, Isaac, Savitz, Adam, Hough, David, Najarian, Dean, Kim, Edward, Gopal, Srihari
Publicado 2016

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia

por Savitz, Adam, Haiyan, Xu, Gopal, Srihari, Nuamah, Isaac, Hough, David, Mathews, Maju, Feng, Yu
Publicado 2016

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A...

por Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Publicado 2020

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

por Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Publicado 2020

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

por Gopal, Srihari, Xu, Haiyan, McQuarrie, Kelly, Savitz, Adam, Nuamah, Isaac, Woodruff, Kimberly, Mathews, Maju
Publicado 2017

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

por Savitz, Adam J, Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Hough, David, Hargarter, Ludger
Publicado 2019

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients...

por Gopal, Srihari, Berwaerts, Joris, Nuamah, Isaac, Akhras, Kasem, Coppola, Danielle, Daly, Ella, Hough, David, Palumbo, Joseph
Publicado 2011

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

por Mathews, Maju, Pei, Huiling, Savitz, Adam, Nuamah, Isaac, Elefant, Erica, Hough, David, Alphs, Larry, Gopal, Srihari
Publicado 2016

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

por Mathews, Maju, Nuamah, Isaac, Savitz, Adam J, Hough, David W, Najarian, Dean, Kim, Edward, Gopal, Srihari
Publicado 2018

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases

por Alphs, Larry, Gopal, Srihari, Karcher, Keith, Kent, Justine, Kern Sliwa, Jennifer, Kushner, Stuart, Nuamah, Isaac, Singh, Jaskaran
Publicado 2011

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate

por Elefant, Erica, Sliwa, Jennifer Kern, Savitz, Adam, Nuamah, Isaac, Mathews, Maju, Gopal, Srihari, Najarian, Dean, Alphs, Larry
Publicado 2016

A Comparative Study of the Efficacy of Intravenous Benzylpenicillin and Intravenous Augmentin in the Empirical Management of Ludwig's Angina

por Boamah, Matthew Owusu, Saheeb, Birch Dauda, Parkins, Grace E., Nuamah, Isaac, Ndanu, Tom Akuetteh, Blankson, Paa-Kwesi
Publicado 2019

Severe odontogenic infections: a 5-year review of a major referral hospital in Ghana

por Blankson, Paa-Kwesi, Parkins, Grace, Boamah, Matthew Owusu, Abdulai, Alhassan Emil, Ahmed, Abdul-Majeed, Bondorin, Sarah, Nuamah, Isaac
Publicado 2019

T45. A COMPARISON OF SCHIZOPHRENIA RELAPSE RATES OF 3 PALIPERIDONE FORMULATIONS, ONCE-DAILY, ONCE-MONTHLY AND ONCE EVERY-3-MONTH: POST-HOC ANALYSIS FROM 3 RANDOMIZED CONTROLLED TRI...

por Mathews, Maju, Gopal, Srihari, Singh, Arun, Nuamah, Isaac, Quinn, Anne Marie, Pungor, Katalin, Tan, Wilson, Soares, Bernardo, Kim, Edward
Publicado 2018

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

por Mathews, Maju, Gopal, Srihari, Singh, Arun, Nuamah, Isaac, Pungor, Katalin, Tan, Wilson, Soares, Bernardo, Kim, Edward, Savitz, Adam J
Publicado 2020

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

por Coppola, Danielle, Liu, Yanning, Gopal, Srihari, Remmerie, Bart, Samtani, Mahesh N, Hough, David W, Nuamah, Isaac, Sulaiman, Ahmad, Pandina, Gahan
Publicado 2012